Venetoclax
As of the edition of 20 October 2026, Venetoclax is a small molecule: marketed, first approved in 2016 (US); acts on BCL2; US protection ends in 2032.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2019
- Kind
- Small molecule
- Brand name
- Venclexta
- First approved
- 11 April 2016 (US)
- Approvals on record
- 15 in 6 regions
- Holder of the most recent approval
- AbbVie; 2 holders in all
- Registered trials
- 680, 102 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Heart and blood vessels; Infections; Skin and connective tissue
US protection
US protection ends in 2032.
The last listed US drug-substance patent ends in 2032. The application that gives this date is held by AbbVie.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product12 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 12 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Venetoclax.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| BCL2 | Apoptosis regulator Bcl-2 | P10415 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 40 | 4 | 23 | 1 |
| Phase 1 | 177 | 55 | 76 | 39 |
| Phase 2 | 389 | 55 | 250 | 59 |
| Phase 3 | 68 | 13 | 52 | 3 |
| Phase 4 | 6 | 1 | 5 | 0 |
| All trials | 680 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AbbVie | Originator, Applicant and Lead sponsor of trials | 2012 to now |